Pathogenetic background for treatment of ascites and hepatorenal syndrome
- 20 September 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Hepatology International
- Vol. 2 (4), 416-428
- https://doi.org/10.1007/s12072-008-9100-3
Abstract
Ascites and hepatorenal syndrome (HRS) are the major and challenging complications of cirrhosis and portal hypertension that significantly affect the course of the disease. Liver insufficiency, portal hypertension, arterial vasodilatation, and systemic cardiovascular dysfunction are major pathophysiological hallmarks. Modern treatment of ascites is based on this recognition and includes modest salt restriction and stepwise diuretic therapy with spironolactone and loop diuretics. Tense and refractory ascites should be treated with a large volume paracentesis, followed by volume expansion or transjugular intrahepatic portosystemic shunt. New treatment strategies include the use of vasopressin V2-receptor antagonists and vasoconstrictors. The HRS denotes a functional and reversible impairment of renal function in patients with severe cirrhosis with a poor prognosis. Attempts of treatment should seek to improve liver function, ameliorate arterial hypotension and central hypovolemia, and reduce renal vasoconstriction. Ample treatment of ascites and HRS is important to improve the quality of life and prevent further complications, but since treatment of fluid retention does not significantly improve survival, these patients should always be considered for liver transplantation.Keywords
This publication has 120 references indexed in Scilit:
- Cardiovascular complications of cirrhosisGut, 2008
- Vaptans: A promising therapy in the management of advanced cirrhosisJournal of Hepatology, 2007
- Guidelines on the management of ascites in cirrhosisGut, 2006
- Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascitesHepatology, 2002
- Nitric oxide and the liverLiver International, 2001
- Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndromeJournal of Hepatology, 1998
- Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trials of spironolactone versus placeboJournal of Hepatology, 1997
- Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide relatedJournal of Hepatology, 1996
- Hemodynamic and humoral changes after liver transplantation in patients with cirrhosisHepatology, 1993
- Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites: Results of a randomized studyJournal of Hepatology, 1992